Prime editing in mice with an engineered pegRNA
CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce...
Gespeichert in:
Veröffentlicht in: | Vascular pharmacology 2024-03, Vol.154, p.107269, Article 107269 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 107269 |
container_title | Vascular pharmacology |
container_volume | 154 |
creator | Salem, Amr R. Bryant, W. Bart Doja, Jaser Griffin, Susan H. Shi, Xiaofan Han, Weihong Su, Yunchao Verin, Alexander D. Miano, Joseph M. |
description | CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit. |
doi_str_mv | 10.1016/j.vph.2023.107269 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2909091252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1537189123001295</els_id><sourcerecordid>2909091252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-2a2a23a1cbe0c28afdaf209792d9b7c282167cc9b0fe139b77e7d215282a577e3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAWxQlmzS-kHiWKyqipdUAUKwthxn0rpqHthJEX_PVCks0SzGd3znSnMIuWR0yihLZ5vprl1POeUCteSpOiJjlkkVi_RGHeM7ETJmmWIjchbChlKWZak6JSORsSRDOSazV-8qiKBwnatXkaujylmIvly3jkwdQb1yNYCHImph9fY8PycnpdkGuDj0Cfm4v3tfPMbLl4enxXwZW0GTLuYGSxhmc6CWZ6YsTMmpkooXKpc44SyV1qqclsAEjiTIgrMEP0yCQkzI9ZDb-uazh9DpygUL262poemD5opiMZ5wtLLBan0TgodSt3iT8d-aUb3npDcaOek9Jz1wwp2rQ3yfV1D8bfyCQcPtYAA8cufA62Ad1BZBebCdLhr3T_wPC3V2aQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2909091252</pqid></control><display><type>article</type><title>Prime editing in mice with an engineered pegRNA</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Salem, Amr R. ; Bryant, W. Bart ; Doja, Jaser ; Griffin, Susan H. ; Shi, Xiaofan ; Han, Weihong ; Su, Yunchao ; Verin, Alexander D. ; Miano, Joseph M.</creator><creatorcontrib>Salem, Amr R. ; Bryant, W. Bart ; Doja, Jaser ; Griffin, Susan H. ; Shi, Xiaofan ; Han, Weihong ; Su, Yunchao ; Verin, Alexander D. ; Miano, Joseph M.</creatorcontrib><description>CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.</description><identifier>ISSN: 1537-1891</identifier><identifier>ISSN: 1879-3649</identifier><identifier>EISSN: 1879-3649</identifier><identifier>DOI: 10.1016/j.vph.2023.107269</identifier><identifier>PMID: 38158001</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; CAPN2 ; CRISPR ; CRISPR-Cas Systems ; DNA - genetics ; Gene Editing - methods ; Mice ; Nucleotides ; Prime editing ; RNA, Guide, CRISPR-Cas Systems</subject><ispartof>Vascular pharmacology, 2024-03, Vol.154, p.107269, Article 107269</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-2a2a23a1cbe0c28afdaf209792d9b7c282167cc9b0fe139b77e7d215282a577e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vph.2023.107269$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38158001$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salem, Amr R.</creatorcontrib><creatorcontrib>Bryant, W. Bart</creatorcontrib><creatorcontrib>Doja, Jaser</creatorcontrib><creatorcontrib>Griffin, Susan H.</creatorcontrib><creatorcontrib>Shi, Xiaofan</creatorcontrib><creatorcontrib>Han, Weihong</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><creatorcontrib>Miano, Joseph M.</creatorcontrib><title>Prime editing in mice with an engineered pegRNA</title><title>Vascular pharmacology</title><addtitle>Vascul Pharmacol</addtitle><description>CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.</description><subject>Animals</subject><subject>CAPN2</subject><subject>CRISPR</subject><subject>CRISPR-Cas Systems</subject><subject>DNA - genetics</subject><subject>Gene Editing - methods</subject><subject>Mice</subject><subject>Nucleotides</subject><subject>Prime editing</subject><subject>RNA, Guide, CRISPR-Cas Systems</subject><issn>1537-1891</issn><issn>1879-3649</issn><issn>1879-3649</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwAWxQlmzS-kHiWKyqipdUAUKwthxn0rpqHthJEX_PVCks0SzGd3znSnMIuWR0yihLZ5vprl1POeUCteSpOiJjlkkVi_RGHeM7ETJmmWIjchbChlKWZak6JSORsSRDOSazV-8qiKBwnatXkaujylmIvly3jkwdQb1yNYCHImph9fY8PycnpdkGuDj0Cfm4v3tfPMbLl4enxXwZW0GTLuYGSxhmc6CWZ6YsTMmpkooXKpc44SyV1qqclsAEjiTIgrMEP0yCQkzI9ZDb-uazh9DpygUL262poemD5opiMZ5wtLLBan0TgodSt3iT8d-aUb3npDcaOek9Jz1wwp2rQ3yfV1D8bfyCQcPtYAA8cufA62Ad1BZBebCdLhr3T_wPC3V2aQ</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Salem, Amr R.</creator><creator>Bryant, W. Bart</creator><creator>Doja, Jaser</creator><creator>Griffin, Susan H.</creator><creator>Shi, Xiaofan</creator><creator>Han, Weihong</creator><creator>Su, Yunchao</creator><creator>Verin, Alexander D.</creator><creator>Miano, Joseph M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202403</creationdate><title>Prime editing in mice with an engineered pegRNA</title><author>Salem, Amr R. ; Bryant, W. Bart ; Doja, Jaser ; Griffin, Susan H. ; Shi, Xiaofan ; Han, Weihong ; Su, Yunchao ; Verin, Alexander D. ; Miano, Joseph M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-2a2a23a1cbe0c28afdaf209792d9b7c282167cc9b0fe139b77e7d215282a577e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>CAPN2</topic><topic>CRISPR</topic><topic>CRISPR-Cas Systems</topic><topic>DNA - genetics</topic><topic>Gene Editing - methods</topic><topic>Mice</topic><topic>Nucleotides</topic><topic>Prime editing</topic><topic>RNA, Guide, CRISPR-Cas Systems</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salem, Amr R.</creatorcontrib><creatorcontrib>Bryant, W. Bart</creatorcontrib><creatorcontrib>Doja, Jaser</creatorcontrib><creatorcontrib>Griffin, Susan H.</creatorcontrib><creatorcontrib>Shi, Xiaofan</creatorcontrib><creatorcontrib>Han, Weihong</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><creatorcontrib>Miano, Joseph M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Vascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salem, Amr R.</au><au>Bryant, W. Bart</au><au>Doja, Jaser</au><au>Griffin, Susan H.</au><au>Shi, Xiaofan</au><au>Han, Weihong</au><au>Su, Yunchao</au><au>Verin, Alexander D.</au><au>Miano, Joseph M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prime editing in mice with an engineered pegRNA</atitle><jtitle>Vascular pharmacology</jtitle><addtitle>Vascul Pharmacol</addtitle><date>2024-03</date><risdate>2024</risdate><volume>154</volume><spage>107269</spage><pages>107269-</pages><artnum>107269</artnum><issn>1537-1891</issn><issn>1879-3649</issn><eissn>1879-3649</eissn><abstract>CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38158001</pmid><doi>10.1016/j.vph.2023.107269</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1537-1891 |
ispartof | Vascular pharmacology, 2024-03, Vol.154, p.107269, Article 107269 |
issn | 1537-1891 1879-3649 1879-3649 |
language | eng |
recordid | cdi_proquest_miscellaneous_2909091252 |
source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
subjects | Animals CAPN2 CRISPR CRISPR-Cas Systems DNA - genetics Gene Editing - methods Mice Nucleotides Prime editing RNA, Guide, CRISPR-Cas Systems |
title | Prime editing in mice with an engineered pegRNA |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T11%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prime%20editing%20in%20mice%20with%20an%20engineered%20pegRNA&rft.jtitle=Vascular%20pharmacology&rft.au=Salem,%20Amr%20R.&rft.date=2024-03&rft.volume=154&rft.spage=107269&rft.pages=107269-&rft.artnum=107269&rft.issn=1537-1891&rft.eissn=1879-3649&rft_id=info:doi/10.1016/j.vph.2023.107269&rft_dat=%3Cproquest_cross%3E2909091252%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2909091252&rft_id=info:pmid/38158001&rft_els_id=S1537189123001295&rfr_iscdi=true |